We used data from the RADAR and SONAR trials that recruited participants with type 2 diabetes and CKD [eGFR 25–75 mL/min/1.73 m2, urine albumin-to-creatinine ratio of 300–5000 mg/g]. The gene discussed is ALB; the disease is type 2 diabetes mellitus.